AllSci News
Hemab doses first volunteer in Phase I trial of HMB-003 for heavy menstrual bleeding
Hemab Therapeutics (Nasdaq: COAG) has dosed the first healthy volunteer in a Phase I trial of HMB-003, a subcutaneous plasmin inhibitor designed ed to...
CHMP's September meeting highlights
The European Medicines Agency’s CHMP recommended 12 new medicines for approval and backed multiple label expansions at its September 14–17 meeting, while...
CHMP backs J&J’s Tecvayli monotherapy after one prior myeloma therapy
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended an indication extension for Johnson & Johnson's Tecvayli...
Vertex withdraws EU filings to expand Kaftrio/Kalydeco to younger children
Vertex Pharmaceuticals has withdrawn EU applications seeking to extend Kaftrio and Kalydeco combination treatment to children with cystic fibrosis aged one...
BMS ends Orum’s AML program, extinguishing USD 80m in remaining milestone obligations
Bristol Myers Squibb (NYSE: BMY) has discontinued development of BMS-986497 (ORM-6151), the CD33-targeting degrader-antibody conjugate (DAC) it acquired...
Ultragenyx secures FDA approval for first treatment of Sanfilippo syndrome type A
The US FDA has granted standard full approval of Fayuvi (rebisufligene etisparvovec-hopf), an AAV9-based gene therapy from Novato, California-based...
Stanford Virtual Biotech links target expression patterns to higher drug success
Stanford Medicine researchers have developed a “Virtual Biotech” comprising tens of thousands of coordinated AI agents organized to mirror the divisions of...
Merz Therapeutics expands Xeomin’s EU/EEA label to pediatric lower limb spasticity in cerebral palsy
Germany-based Merz Therapeutics has received EU/EEA approval for Xeomin (incobotulinumtoxinA) to treat spasticity associated with pes equinus in children...
Avacta’s FAP-activated exatecan PDC shows early clinical proof of mechanism
Avacta reported preliminary Phase Ia data for AVA6103, a fibroblast activation protein (FAP)-activated peptide-drug conjugate delivering the topoisomerase I...
WuXi XDC grants Ona exclusive global license to WuXiTecan-2 for single ADC
Spain-based Ona Therapeutics has licensed WuXi XDC Cayman Inc.'s (HKEX: 2268) proprietary WuXiTecan-2 exatecan-based payload-linker platform on an exclusive...
Dualitas lands USD 36.5m upfront in Roche bispecific discovery deal worth up to USD 1b
South San Francisco-based Dualitas Therapeutics has signed a research collaboration and license agreement with Roche, granting the Swiss pharma access to...
Boston Children’s-led team develops prime assembly for large DNA insertions
A new genome editing approach that can insert DNA payloads of up to approximately 12 kilobases into defined genomic locations without generating...
Lisata pivots from oncology to metabolic disease with Marea acquisition and USD 225m financing
Lisata Therapeutics has acquired Marea Therapeutics in a stock-for-stock transaction and closed a concurrent USD 225 million private placement, in a deal...
North Immunology to go public via Aethlon reverse merger backed by USD 180m PIPE
San Diego-based Aethlon Medical, Inc. (Nasdaq: AEMD) has agreed to merge with North Immunology, Inc. in an all-stock transaction that will take the atopic...
Matisse secures EUR 14m Series A to advance isupartob sodium into Phase II sepsis trial
Netherlands-based Matisse Pharmaceuticals B.V. has closed a EUR 14 million Series A financing round to fund a Phase II clinical trial of isupartob sodium,...
The AllSci Brief
Free, systematic R&D and deal news. Daily.